Today on #RareDiseaseDay, we highlight the power of listening. With our support, #policlinicogemelli created a documentary, sharing the stories of Enrico, Hermes & Luca - 3 young men living with #Duchenne 💛
Watch it here: https://t.co/JhXx6fhmxQ
Sperogenix Therapeutics, #Santhera's specialized rare disease partner for China, announced: 曙方医药杜氏肌营养不良新药Vamorolone上市许可申请获受理! China's NMPA has accepted for priority review the NDA for this new medicine to treat #DMD. More at https://t.co/CL4T2oT2Io #Duchenne
At #Santhera, we recognize the vital significance of #InternationalWomensDay in celebrating the achievements and contributions of women worldwide. Together, let's continue to champion for opportunities for women in our organization and beyond.
#IWD2024#EmpowerWomen#WomenLeaders
We are thrilled to announce that the U.S. FDA has approved our novel corticosteroid drug for the treatment of #Duchenne muscular dystrophy (#DMD) in children and adults aged 2 years and older.
Read more here https://t.co/6bTOWoOrVt.
#Santhera#theirfutureourfocus
We're at the H.C. Wainwright & Co, LLC 25th Annual Global Investment Conference in NYC! Our CEO Dario Eklund will share updates and future goals of #Santhera. Join him on Sep 12, 2023, at 10:00 AM EDT, room Kennedy II, Lotte NY Palace Hotel. #HCWainright#investorconference#DMD
Today, #Santhera announced its half-year 2023 results and provided updates on its business and financing initiatives. Progress made will also be shared in a conference call today at 14:30 CEST / 08:30 EST. Join us! For dial-in details and PR: https://t.co/M6ENVuI7kp.
#Santhera is excited to be attending the #PPMD Annual Conference Jun 29-Jul 1 in Dallas, TX! Join us for the “Potential Upcoming Approvals” presentation on Friday, June 30, where Tom White, Field Medical Director, Santhera will be one of the featured presenters. #Duchenne#DMD
#Santhera just announced its preliminary unaudited 2022 financial results , reported on progress with its lead DMD drug candidate, and provided updates on its strategic and financing initiatives. Visit our press release & conference call replay here https://t.co/WjBJ8LyTWT.
Vamorolone NDA mid-cycle review meeting by FDA completed! “We'll work closely with FDA during the remainder of the review process and are confident about being able to provide an emerging therapy soon,” said Shabir Hasham, MD, #Santhera's CMO. https://t.co/aB30UUDUjw #duchenne
Excited to be at the #CureDuchenne Futures Conference in San Diego/CA which is focused on bringing education, connection, and hope to the #Duchenne community. Visit our booth to learn about our mission to improve the lives of those living with #DMD. #Santhera#theirfutureourfocus
Next week, #CureDuchenne will bring patients, caregivers & HCPs together for the CureDuchenne Futures Conference. We are proud to have Rob Halter, Field Medical Director, speaking as part of a panel on preserving muscle during Friday’s (April 21) agenda. #santhera#Duchenne#DMD
Proud to be a partner of @mdaorg’s 2023 MDA Clinical & Scientific Conference in Dallas, March 19-22. The conference will explore the latest research advancements & clinical achievements in #neuromuscular disease. Learn more: https://t.co/JtJ1zLvFLc #MDAconference#MDA#Santhera